Trial reportTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer.
Trial report in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Trial
- Pancreatic Cancer: Pathogenesis and Clinical Studies.MedComm · 2025Review
- Hacking Pancreatic Cancer: Present and Future of Personalized Medicine.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities.Cancers · 2021Review
- A peptide-CpG-DNA-liposome complex vaccine targeting TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft model.OncoTargets and therapy · 2018Article
- Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review.World journal of gastroenterology · 2017Review
- The efficacy of a new high intensity focused ultrasound therapy for locally advanced pancreatic cancer.Journal of cancer research and clinical oncology · 2017Article
- Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.International journal of molecular sciences · 2017Review
- Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience.Oncotarget · 2016Article
- Pancreatic cancer from bench to bedside: molecular pathways and treatment options.Annals of translational medicine · 2016Review
- State of the art biological therapies in pancreatic cancer.World journal of gastrointestinal oncology · 2016Review
- Pancreatic Cancer from Molecular Pathways to Treatment Opinion.Journal of Cancer · 2016Review
- Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report.World journal of gastroenterology · 2015Article
- [Nimotuzumab significantly enhances chemosensitivity of PC9 human lung adenocarcinoma cells to paclitaxel in vitro].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2015Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced pancreatic cancer patients have poor prognosis and scarcely respond to conventional therapies. Clinical trials support the use of molecular-targeted therapy against epidermal growth factor receptor (EGFR) signaling. The objective of the current study was to evaluate the contribution of a monoclonal antibody against EGFR, nimotuzumab, to standard gemcitabine therapy. Patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma were assigned to receive gemcitabine plus nimotuzumab. The primary end point was overall survival, whereas the secondary end points included progression-free survival, objective response, and adverse side effects. A total of 18 eligible patients were accrued between December 2007 and July 2010. The disease control rate, calculated as the sum of complete response, partial response, and stable disease, was 55.6%. The median overall survival time was 9.29 months (95% CI, 5.499 to 13.072). The median progression-free survival was 3.71 months (95% CI, 2.526 to 4.902), and the 1-year survival rate was 38.9%. Of all the patients, 88.8% had at least one adverse side effect; however, no grade 4 adverse side effect was reported. Nimotuzumab as a high-purity humanized monoclonal antibody with favorable safety profile, its value in the treatment of pancreatic cancer along with gemcitabine, particularly in the comprehensive treatment of advanced pancreatic cancer, is appealing for further prospective randomized large-scale clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.